Monday, November 27 | 8:30 a.m.-8:40 a.m. | M1-SSNMMI02-4 | Room E350
A study will be presented in this session that compared whole-body MRI, whole-body F-18 FDG-PET/MRI, and conventional imaging (CT, axillary sonography, and bone scintigraphy) for staging women with newly diagnosed breast cancer.
Presenter Janna Morawitz, MD, of the University Hospital Düsseldorf in Germany, and colleagues compared the approaches in 208 women who were on average 53.5 years old. Images were evaluated separately regarding lesion count, lesion localization, and lesion characterization, with histopathology and follow-up imaging serving as the reference standard.
Findings in nodal staging of primary breast cancer patients showed that F-18 FDG-PET/MRI had a significantly better diagnostic performance than MRI alone and conventional staging, while no significant differences were seen in the detection of distant metastases.
“F-18 FDG PET/MRI can be reliably used for staging purposes in patients with newly diagnosed breast cancer,” Morawitz et al noted.
Check out this molecular imaging session on breast cancer for all the details.
